Rikin Kadakia, MD
Interventional Cardiology · Salinas, CANPI 1154718526
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,134 of the $238,386 with a category attached, or 66.3%. 50 manufacturers reported payments, led by Novo Nordisk at 57.8% of the total. 2025 is the largest year on record at $115,706, more than ten times the $565 reported in 2019. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 662 payments — averaging $360.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$138K
- Shockwave Medical, Inc$79K
- Edwards Lifesciences$4K
- Abbott$3K
- Abiomed$2K
- Medtronic$2K
- plus $11K from 44 others
What the payments were for
- Consulting fees$19,2828%
- Speaking & faculty fees$158,13466%
- Grants$2000%
- Travel & lodging$31,88613%
- Food & beverage$28,22012%
- Education$4710%
- Gifts$840%
- Entertainment$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$79,523
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$78,680
- FLOWTRIEVER CATHETER, S$726
- Edwards SAPIEN 3 Transcatheter Heart Valve$644
- COREVALVE EVOLUT R$574
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$437
- Orsiro Mission$432
- Impella$410
- Cook$297
- MitraClip$286
- PRO-Kinetic Energy$282
- PK Papyrus$282
- Passeo-18$282
- LifeVest$272
- RESOLUTE ONYX$179
- Diamondback Coronary$173
- Diamondback Peripheral$173
- ONYX FRONTIER$172
- NHancer Rx$150
- TrapIT$150
How this compares
$238,386 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 138 | $153,301 |
| XareltoRivaroxaban | 19 | $29,405 |
| OzempicSemaglutide | 12 | $10,257 |
| Repatha SureclickEvolocumab | 11 | $7,108 |
| Rosuvastatin Calcium | 173 | $3,480 |
| Amiodarone Hcl | 46 | $1,898 |
| Metoprolol Succinate | 164 | $1,834 |
| ClopidogrelClopidogrel Bisulfate | 128 | $1,488 |
| Bumetanide | 37 | $1,095 |
| Atorvastatin Calcium | 135 | $1,064 |
| Carvedilol | 102 | $639 |
| Doxazosin Mesylate | 34 | $566 |
| Losartan Potassium | 71 | $560 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 42 | $521 |
| Ezetimibe | 13 | $521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $418 | $153,301138 claims |
| Johnson & JohnsonXarelto | $25 | $29,40519 claims |
| Novo NordiskOzempic | $137,856 | $10,25712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Salinas
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.